Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 291-300

  Schutz, Fabio A B ^a   Je, Youjin ^b   Choueiri, Toni K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anemia; Bone marrow toxicities; Hematologic toxicities; Lymphopenia; Meta analysis; Neutropenia; Sorafenib; Targeted therapy; Thrombocytopenia; Tyrosine kinase inhibitors; Vascular endothelial growth factor receptor

Indexed keywords

CARBOPLATIN; DACARBAZINE; PACLITAXEL; PLACEBO; SORAFENIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 80053973209     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.11.007     Document Type: Article

References (42)

1. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
2. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
3. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
4. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
5. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
6. Choueiri T.K., Schutz F.A., Je Y., et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.
7. Wu S., Chen J.J., Kudelka A., et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:117-123.
8. Chu D., Lacouture M.E., Fillos T., Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47:176-186.
9. Tian X., Kaufman D.S. Differentiation of embryonic stem cells towards hematopoietic cells: progress and pitfalls. Curr Opin Hematol 2008, 15:312-318.
10. Lancrin C., Sroczynska P., Serrano A.G., et al. Blood cell generation from the hemangioblast. J Mol Med 2010, 88:167-172.
11. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958.
12. Hattori K., Heissig B., Wu Y., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002, 8:841-849.
13. Katoh O., Tauchi H., Kawaishi K., et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995, 55:5687-5692.
14. Barleon B., Sozzani S., Zhou D., et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
15. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
16. Rasko J.E., Metcalf D., Rossner M.T., et al. The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia 1995, 9:2058-2066.
17. Kumar R., Crouthamel M.C., Rominger D.H., et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009, 101:1717-1723.
18. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62:1006-1012.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
21. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
22. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
23. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
24. Hahn O.M., Yang C., Medved M., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
25. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
26. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
27. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008, 26:2178-2185.
28. Okita K., Imanaka K., Chida N., et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). ASCO Gastrointestinal Cancers Symposium 2010, Abstr. LBA128.
29. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53:1119-1129.
30. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
31. Kilickap S., Abali H., Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003, 21:3542. author reply 3543.
32. van der Veldt A.A., Boven E., Vroling L., et al. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 2009, 27:1339-1340. author reply 1340-1332.
33. Alexandrescu D.T., McClure R., Farzanmehr H., Dasanu C.A. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008, 26:4047-4048.
34. Pessina A., Malerba I., Gribaldo L. Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr Pharm Des 2005, 11:1055-1065.
35. Gabbianelli M., Pelosi E., Montesoro E., et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995, 86:1661-1670.
36. Rusten L.S., Lyman S.D., Veiby O.P., Jacobsen S.E. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood 1996, 87:1317-1325.
37. Mackarehtschian K., Hardin J.D., Moore K.A., et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995, 3:147-161.
38. Crump M., Hedley D., Kamel-Reid S., et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010, 51:252-260.
39. Nguyen T.K., Jordan N., Friedberg J., et al. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 2010, 34:379-386.
40. Ramakrishnan V., Timm M., Haug J.L., et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010, 29:1190-1202.
41. Ravandi F., Cortes J.E., Jones D., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
42. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.